All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
eGvHD app for GvHD assessment
E-tools can improve the accuracy of GvHD assessment and also can enhance the validity of research findings and clinical observations. These tools offer an easy and intuitive access to the latest guidelines, as well as provide automated help in applying complex decision algorithms. The eGvHD App was recently developed for these very reasons.
On Wednesday 21 March 2018 during an oral abstract session at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Lisbon, Portugal, Hélène M Schoemans from UZ Leuven, Leuven, Belgium, reported results on behalf of her colleagues of a study which aimed to evaluate the present clinical procedures in GvHD assessment, the additional significance of using the eGvHD App compared with standard methods on the accuracy, reliability and time needed to assess GvHD.
HCPs were divided into two groups: the first group were allocated to use the App (App group), the second group used their usual GvHD assessment guides (UM group) to evaluate the diagnosis and severity score of 10 clinical vignettes validated by a group of separate GvHD experts (gold standard), who implemented the MAGIC and NIH 2014 guidelines for acute (4 vignettes) and chronic (6 vignettes) GvHD. Seven Belgian allogenic HCT centers contributed to this study, covering >80% of the national HCT activity. In total, 77 HCPs completed the assessment.
Key findings:
- Number of vignettes for correct diagnosis in the App group and the UM group: 10 vs 5, OR = 6.14 (95% CI, 2.83–13.34), P < 0.001
- Number of vignettes for GvHD scoring in the App and the UM groups: 9 vs5, OR = 6.29 (95% CI 4.32–9.15), P < 0.001
- Assessment of GvHD was significantly better in the App group: aGvHD OR = 17.89 (95% CI 8.47–37.79) and cGvHD OR = 4.34 (95% CI 2.79–6.74), respectively, P < 0.001
- Inter-observer agreement in the App group and the UM group: 0.46 (95% CI, 0.23–0.68) vs 12 (95% CI, 0.03–0.21), P = 0.003
Doctor Schoemans concluded by stating that “using the eGvHD App showed superior accuracy and reliability for GvHD assessment compared to usual care. The eGvHD app has therefore the potential to improve the quality of GvHD data in clinical research and practice.”
References